Leber’s Amaurosis Gene Therapy: How It Works, Results and What to Expect

Leber's amaurosis gene therapy is an eye treatment designed for a specific inherited form of Leber congenital amaurosis caused by changes in both copies of the RPE65 gene. It delivers a working version of that gene to retinal cells and may improve usable vision, particularly in low light, in people who still have enough viable retinal cells.

Overview: what Leber's amaurosis gene therapy does

Leber’s amaurosis gene therapy refers most often to treatment for Leber congenital amaurosis (LCA) or related inherited retinal dystrophy caused by disease-causing changes in the RPE65 gene. The available therapy supplies a functional copy of this gene to selected cells in the retina, the light-sensitive tissue at the back of the eye. It is intended to support the visual cycle, a process the eye needs to respond to light.

LCA is a group of rare inherited conditions that usually cause severe visual impairment from infancy or early childhood. Different genes can cause LCA, and these genetic forms can affect the retina in different ways. Leber congenital amaurosis therefore requires individualized assessment rather than a one-size-fits-all treatment approach.

For people with confirmed biallelic RPE65 mutations and sufficient remaining retinal cells, gene therapy may improve functional vision. This can mean better navigation in dim environments, greater light sensitivity, or improved ability to perform daily activities. Results vary, and the treatment cannot replace retinal cells that have already been lost.

Is there a gene therapy for Leber's amaurosis?

Yes. An approved gene therapy, voretigene neparvovec, is available in some countries for inherited retinal disease caused by mutations in both copies of the RPE65 gene. It may be used for eligible children and adults with LCA or retinitis pigmentosa linked to this gene. It is commonly known by the brand name Luxturna.

This treatment does not apply to all forms of LCA. More than one gene may lead to the LCA pattern of early-onset retinal dysfunction, and each gene has a different role in vision. At present, a person with LCA caused by a gene other than RPE65 would not be expected to benefit from this particular therapy.

Research is continuing into gene replacement, gene editing, RNA-based therapies, cell therapies, and neuroprotective approaches for other inherited retinal diseases. Clinical trials may be appropriate for some patients, but an experimental treatment should be discussed carefully with a retinal specialist and genetic team.

How the treatment works and who may be eligible

In RPE65-related disease, retinal pigment epithelial cells cannot make enough functional RPE65 protein. This protein is needed to recycle vitamin A derivatives within the visual cycle. Without it, rod cells, which are especially important for vision in low light, cannot respond normally to light even when some retinal tissue remains.

Gene therapy uses a modified adeno-associated virus as a delivery vehicle. The virus is designed to carry a working copy of the RPE65 gene into retinal cells; it is not intended to cause infection. Once inside targeted cells, the gene can provide instructions for making the missing or reduced protein and may help the remaining retinal cells function more effectively.

Candidacy depends on more than a genetic result. Specialists usually confirm disease-causing changes in both copies of RPE65, document retinal function and structure, and assess whether there are enough viable retinal cells. The evaluation may include a detailed eye examination, retinal photography, optical coherence tomography, visual field testing, functional vision assessment, and genetic counselling.

Age alone does not determine eligibility. However, treatment is generally considered before progressive retinal degeneration has left very limited viable tissue. A retinal specialist can explain whether gene therapy evaluation is appropriate and whether local regulatory approval and access criteria are met.

Step by step: what happens during the procedure

Before treatment, the ophthalmology team reviews imaging, genetic findings, medications, overall health, and anaesthesia needs. Patients usually receive a short course of corticosteroid medication around the procedure to help reduce inflammation. The prescribing clinician provides individualized instructions, including how to take medicines and which medicines may need adjustment.

The treatment is given in an operating room by a vitreoretinal surgeon. After anaesthesia, the surgeon performs a vitrectomy, removing the gel-like vitreous from inside the eye. A small amount of gene therapy is then injected into the space beneath the retina, known as the subretinal space, to create a temporary small retinal elevation called a bleb.

Only one eye is treated at a time. If both eyes are eligible, the second eye is generally treated after the first eye has had time to recover, according to the approved protocol and the treating team’s advice. The procedure is highly specialized, so it should be performed by an experienced retinal surgical and inherited retinal disease team.

After surgery, the eye may be covered temporarily. The patient receives instructions about eye drops, activity restrictions, positioning if required, and follow-up appointments. Family support can be helpful, particularly for children and for people with significant visual impairment.

Recovery timeline, benefits and realistic expectations

In the first days after surgery, blurred vision, redness, discomfort, sensitivity to light, or a scratchy sensation may occur. These symptoms often improve as the eye heals, but any severe pain, sudden vision change, increasing redness, or new flashing lights should be reported urgently. Follow-up visits allow the team to monitor healing, eye pressure, inflammation, and retinal status.

Vision changes are not always immediate. Some people notice better light sensitivity or navigation over the weeks and months after treatment. Functional measures, such as moving through a dimly lit environment, may show improvement even if standard visual acuity testing changes only modestly. Each person’s result depends on their retinal health before treatment and the nature of their disease.

The primary potential benefit is improved use of remaining vision, especially in low-light settings. Gene therapy may support greater independence in daily activities for some people, but it does not create normal eyesight, cure the underlying inherited condition in every retinal cell, or reliably stop all future retinal degeneration.

Low-vision rehabilitation remains valuable before and after treatment. Visual aids, orientation and mobility training, educational support, workplace adaptations, and emotional support can help patients use their vision safely and confidently. These supports should not be viewed as a failure of treatment; they are an important part of comprehensive care.

Can gene therapy restore vision?

Gene therapy can improve functional vision in some eligible people with RPE65-related LCA, but it cannot reliably restore normal vision. It works best when the retina still contains living cells that can respond once the missing genetic instruction is delivered. It cannot replace retinal cells that have already degenerated.

Improvement may be most noticeable in dim light, where people may find it easier to orient themselves, recognize surroundings, or move through an environment. Changes in visual acuity, visual field, contrast sensitivity, and color vision are less predictable. Results also differ between individuals and between eyes.

A specialist should discuss treatment goals in practical terms. For example, a meaningful result may involve improved mobility at dusk or indoors rather than being able to read small print without assistance. Ongoing eye monitoring is still needed after therapy because inherited retinal disease may continue to change over time.

How risky is gene therapy?

Gene therapy for RPE65-related retinal disease involves both eye surgery and a biological treatment, so it has potential risks. Most safety concerns relate to the subretinal injection and vitrectomy rather than to a general viral illness. The delivery vector is modified and is not designed to reproduce in the body or cause infection.

Possible complications include inflammation inside the eye, raised eye pressure, cataract, retinal tears or detachment, infection, bleeding, or a reduction in vision. Less common effects may include changes in the central retina, including thinning or loss of retinal tissue. The treating team monitors closely for these problems because early recognition can be important.

Systemic immune reactions are considered uncommon with local eye delivery, but corticosteroids are used around treatment to reduce inflammation. Patients should tell their team about all medicines, allergies, pregnancy status where relevant, and any history of eye surgery or eye disease. The decision should balance the potential benefit against the individual eye’s condition and surgical risk.

What is the prognosis for Leber congenital amaurosis?

The prognosis for Leber congenital amaurosis varies widely because LCA is a group of genetic retinal conditions rather than one single disease. Many people have significant visual impairment from early life, and some forms cause further loss of vision over time. Other forms may be more stable or retain useful vision for longer.

Genetic diagnosis helps clarify the likely disease course, identify potential treatments, guide screening for associated health concerns in certain genetic syndromes, and support family planning discussions. Regular review with an inherited retinal disease specialist allows care to adapt as visual needs change.

Even when a disease-modifying therapy is not available, children and adults can benefit from early low-vision services, educational planning, mobility support, assistive technology, and psychological support. These measures can improve participation, independence, and quality of life.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can assess inherited retinal conditions and coordinate ophthalmology, genetic counselling, imaging, rehabilitation, and treatment planning for international patients.

When to seek medical care

Parents or caregivers should arrange an ophthalmology assessment if an infant or child has very poor visual attention, does not follow faces or lights as expected, has nystagmus (involuntary eye movements), frequently presses or rubs the eyes, or has marked difficulty in dim light. These signs can have several causes, and prompt assessment helps identify treatable conditions and appropriate support.

People with known or suspected inherited retinal disease should seek care from an ophthalmologist with expertise in retinal disorders and consider genetic counselling. A new change in vision, flashes of light, a sudden increase in floaters, a curtain-like shadow, severe eye pain, or increasing redness after eye surgery needs urgent medical assessment.

Family members may wish to discuss genetic counselling because inheritance patterns and recurrence risks differ by gene. Testing should be interpreted in clinical context; a genetic result alone may not establish eligibility for gene therapy.

Frequently asked questions

Who can receive Leber's amaurosis gene therapy?

Eligibility generally requires confirmed disease-causing mutations in both copies of the RPE65 gene and enough remaining viable retinal cells. A retinal specialist uses genetic testing, retinal imaging, and functional vision testing to determine whether treatment may be suitable. Availability may also depend on local approval criteria.

Is gene therapy a cure for Leber congenital amaurosis?

No. The currently available treatment is not a cure for all forms of LCA and is only intended for RPE65-related inherited retinal disease. It may improve the function of remaining retinal cells, but it cannot replace cells that are already lost or guarantee that disease progression will stop.

Can adults have RPE65 gene therapy?

Adults may be considered if they meet the genetic and retinal eligibility requirements. The key issue is whether sufficient viable retinal tissue remains, rather than age alone. An inherited retinal disease specialist can assess the likely balance of benefits and risks.

How long does recovery take after retinal gene therapy?

Initial surgical healing takes days to weeks, while changes in functional vision may develop over weeks or months. Follow-up schedules vary, but regular early appointments are needed to monitor inflammation, eye pressure, and retinal healing. The care team will provide specific activity and medication instructions.

Will vision continue to worsen after gene therapy?

It is possible. Gene therapy can improve retinal function in eligible patients, but it may not prevent all long-term retinal degeneration. Continued eye examinations and low-vision support remain important after treatment.

Does genetic testing matter if a person already has an LCA diagnosis?

Yes. LCA can be caused by changes in many different genes, while the approved gene therapy targets RPE65-related disease. Genetic testing helps confirm the cause, clarify potential eligibility, and guide counselling for the patient and family.

References

• United States Food and Drug Administration
• American Academy of Ophthalmology
• National Eye Institute
• European Medicines Agency
• Foundation Fighting Blindness

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.